Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
暂无分享,去创建一个
R. Hui | Yuan-Tsong Chen | Chien-Hsiun Chen | C. Chu | Zhi-sheng Liu | W. Chung | S. Hung | M. Hsih
[1] M. Nelson,et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients , 2009, Pharmacogenetics and genomics.
[2] C. Hsiao,et al. Oxcarbazepine‐induced Stevens–Johnson syndrome in a patient with HLA‐B*1502 genotype , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] Sheau-Fang Yang,et al. Oxcarbazepine‐induced Stevens‐Johnson Syndrome: A Case Report , 2009, The Kaohsiung journal of medical sciences.
[4] K. Suphapeetiporn,et al. Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.
[5] Yuan-Tsong Chen,et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.
[6] C. Sotozono,et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.
[7] C. Bazil,et al. Cross-sensitivity of skin rashes with antiepileptic drug use , 2008, Neurology.
[8] M. Muramatsu,et al. Human leukocyte antigen genotypes in carbamazepine‐induced severe cutaneous adverse drug response in Japanese patients , 2008, The Journal of dermatology.
[9] S. Lydersen,et al. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs , 2008, Epilepsy Research.
[10] R. Toledano,et al. Adverse Effects of Antiepileptic Drugs , 2008, Seminars in neurology.
[11] L. Naldi,et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.
[12] T. Shiohara,et al. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. , 2008, Acta dermato-venereologica.
[13] S. Lhatoo,et al. CNS Adverse Events Associated with Antiepileptic Drugs , 2008, CNS drugs.
[14] L. Naldi,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.
[15] L. Hirsch,et al. Comparison and predictors of rash associated with 15 antiepileptic drugs , 2007, Neurology.
[16] P. Kwan,et al. Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.
[17] E. Bröcker,et al. Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[18] M. Pirmohamed,et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.
[19] M. Neuman,et al. Antiepileptic drug-induced hypersensitivity syndrome reactions. , 2006, Current drug safety.
[20] S. Jee,et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.
[21] W. Pan,et al. Han Chinese Cell and Genome Bank in Taiwan: Purpose, Design and Ethical Considerations , 2006, Human Heredity.
[22] M. Schumacher,et al. A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.
[23] B. Thiers. HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .
[24] Yuan-Tsong Chen,et al. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. , 2005, Personalized medicine.
[25] Yuan-Tsong Chen,et al. Erratum: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol (Proceedings of the National Academy of Sciences of the United States of America (March 15, 2005) 102, 11 (4134-4139)) , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Yoshita,et al. MRI of segmental zoster paresis , 2005, Neurology.
[27] Martine Bagot,et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. , 2004, The Journal of allergy and clinical immunology.
[28] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[29] S. Helmers,et al. The new antiepileptic drugs: scientific review. , 2004, JAMA.
[30] D. Middleton. Current and emerging technology for HLA typing , 2002, International journal of hematology.
[31] K. Tokunaga,et al. Diversity of HLA among Taiwan's indigenous tribes and the Ivatans in the Philippines. , 2001, Tissue antigens.
[32] S. Knowles,et al. Anticonvulsant Hypersensitivity Syndrome , 1999, Drug safety.
[33] B. Wilder. How About the New Antiepileptic Drugs? , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[34] J. Roujeau. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. , 1994, The Journal of investigative dermatology.
[35] B. Haldane. THE ESTIMATION AND SIGNIFICANCE OF THE LOGARITHM OF A RATIO OF FREQUENCIES , 1956, Annals of human genetics.